Drugs / LY3405105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03770494 | Jan 2019 → Feb 2021 | cancer | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3405105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03770494 ↗ |
| Action | Inhibit | “a covalent inhibitor of cyclin-dependent kinase 7 (CDK7)” PMID 37531083 ↗ Jan 2024 |
| Route | Oral | “LY3405105 monotherapy was given once daily (QD; part A1) or thrice weekly (TIW; part A2) starting at 1 and 2 mg orally, respectively” PMID 37531083 ↗ Jan 2024 |
| Target | CDK7 | “a covalent inhibitor of cyclin-dependent kinase 7 (CDK7)” PMID 37531083 ↗ Jan 2024 |